Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02389127 · ClinicalTrials.gov registry record

Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis

A clinical trial, sponsored by University of Arkansas.

Completed
Registry status
50
Enrollment target

NCT02389127: Completed study, sponsored by University of Arkansas.

NCT02389127 is a clinical trial that has completed, run by University of Arkansas. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02389127 has completed, sponsored by University of Arkansas.

COMPLETED
Registry status
50 participants
Enrollment target

Study Summary

Cirrhosis and advanced liver disease have been associated with an increased risk for hyperglycemia and type 2 diabetes mellitus (T2DM). The diagnostic yield of common tests used to define diabetes and insulin resistance in the general population differs significantly from the one observed in patients with liver disease. Glycosylated hemoglobin A1c (HbA1c), a reliable test to assess chronic glycemia and recommended both for the diagnosis and monitoring of T2DM, is neither accurate nor reliable in patients with cirrhosis. A validation study has not been performed to define its true usefulness in the setting of cirrhosis. The study aims to determine the level of HbA1c that better corresponds to the diagnosis of T2DM - as determined by an oral glucose tolerance test (OGTT) - and to correlate the levels of HbA1c with the average glucose over a 12-week period in patients with cirrhosis and known T2DM, in cirrhotic patients with different degrees of liver impairment as compared to patients with T2DM and no liver disease.

Primary Outcome

Patients with cirrhosis and varying degrees of liver dysfunction but no prior diagnosis of T2DM will have an OGTT performed after overnight fasting (8-12-hours).

Interventions

  • DEVICE Continuous glucose monitor (Dexcom, San Diego, CA)

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2015-07
Est. Completion 2017-06-01
University of Arkansas

318 total trials

What the finished NCT02389127 record still lists

NCT02389127 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Continuous glucose monitor (Dexcom, San Diego, CA) is the first listed.

NCT02389127 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02389127 about?

NCT02389127 is a clinical study titled "Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis". Cirrhosis and advanced liver disease have been associated with an increased risk for hyperglycemia and type 2 diabetes mellitus (T2DM). The diagnostic yield of common tests used to define diabetes and insulin resistance in the general population differs significantly from the one observed in patient...

What is the current status of trial NCT02389127?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2015-07. Estimated completion is 2017-06-01.

What interventions are being tested in trial NCT02389127?

The interventions under investigation include: Continuous glucose monitor (Dexcom, San Diego, CA) (DEVICE).

Who is sponsoring clinical trial NCT02389127?

This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02389127, the US trial registry maintained by the National Library of Medicine. NCT02389127 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.